Michael Schmidt
Stock Analyst at Guggenheim
(4.89)
# 67
Out of 5,182 analysts
127
Total ratings
69.61%
Success rate
44.76%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Schmidt
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NBTX Nanobiotix | Maintains: Buy | $26 → $36 | $30.81 | +16.85% | 4 | Apr 2, 2026 | |
| ZNTL Zentalis Pharmaceuticals | Reiterates: Buy | $6 | $2.76 | +117.39% | 4 | Mar 27, 2026 | |
| CMPX Compass Therapeutics | Reiterates: Buy | $12 | $5.40 | +122.22% | 6 | Mar 24, 2026 | |
| CTMX CytomX Therapeutics | Maintains: Buy | $10 → $15 | $4.25 | +252.94% | 3 | Mar 18, 2026 | |
| GLUE Monte Rosa Therapeutics | Maintains: Buy | $34 → $30 | $17.12 | +75.23% | 3 | Mar 18, 2026 | |
| ERAS Erasca | Maintains: Buy | $12 → $20 | $16.94 | +18.06% | 2 | Mar 16, 2026 | |
| XFOR X4 Pharmaceuticals | Initiates: Buy | $12 | $4.05 | +196.30% | 1 | Mar 9, 2026 | |
| TNGX Tango Therapeutics | Maintains: Buy | $18 → $20 | $20.06 | -0.30% | 3 | Mar 6, 2026 | |
| ONC BeOne Medicines AG | Maintains: Buy | $400 → $410 | $312.19 | +31.33% | 5 | Feb 27, 2026 | |
| GMAB Genmab | Maintains: Buy | $45 → $40 | $28.40 | +40.85% | 4 | Feb 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $92 → $160 | $96.75 | +65.37% | 5 | Jan 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $35 | $21.70 | +61.29% | 4 | Dec 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $4.89 | +145.40% | 1 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $125 | $95.89 | +30.36% | 7 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $3.73 | +168.10% | 6 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $9.05 | +98.90% | 6 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $15 | $11.21 | +33.81% | 6 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $17 | $36.95 | -53.99% | 1 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $45 | $25.25 | +78.22% | 2 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $15 | $19.10 | -21.47% | 1 | May 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $52 | $87.13 | -40.32% | 1 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $10 | $14.51 | -31.08% | 1 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $32 | $24.56 | +30.29% | 3 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $14 | $5.45 | +156.88% | 3 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $18.30 | - | 1 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $42 | $44.20 | -4.98% | 10 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $2.29 | - | 1 | Jan 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $20 | $5.22 | +283.14% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $31.85 | - | 3 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $112 | $6.55 | +1,609.92% | 4 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.60 | - | 2 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $5.50 | - | 2 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.70 | - | 1 | Jan 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $34 | $12.25 | +177.55% | 4 | Nov 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $26 | $2.66 | +877.44% | 1 | May 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.55 | - | 2 | Apr 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $80 | $33.77 | +136.90% | 5 | Feb 15, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $7.30 | - | 6 | Jan 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $4 → $5.5 | $4.38 | +25.57% | 2 | Nov 7, 2017 |
Nanobiotix
Apr 2, 2026
Maintains: Buy
Price Target: $26 → $36
Current: $30.81
Upside: +16.85%
Zentalis Pharmaceuticals
Mar 27, 2026
Reiterates: Buy
Price Target: $6
Current: $2.76
Upside: +117.39%
Compass Therapeutics
Mar 24, 2026
Reiterates: Buy
Price Target: $12
Current: $5.40
Upside: +122.22%
CytomX Therapeutics
Mar 18, 2026
Maintains: Buy
Price Target: $10 → $15
Current: $4.25
Upside: +252.94%
Monte Rosa Therapeutics
Mar 18, 2026
Maintains: Buy
Price Target: $34 → $30
Current: $17.12
Upside: +75.23%
Erasca
Mar 16, 2026
Maintains: Buy
Price Target: $12 → $20
Current: $16.94
Upside: +18.06%
X4 Pharmaceuticals
Mar 9, 2026
Initiates: Buy
Price Target: $12
Current: $4.05
Upside: +196.30%
Tango Therapeutics
Mar 6, 2026
Maintains: Buy
Price Target: $18 → $20
Current: $20.06
Upside: -0.30%
BeOne Medicines AG
Feb 27, 2026
Maintains: Buy
Price Target: $400 → $410
Current: $312.19
Upside: +31.33%
Genmab
Feb 23, 2026
Maintains: Buy
Price Target: $45 → $40
Current: $28.40
Upside: +40.85%
Jan 20, 2026
Maintains: Buy
Price Target: $92 → $160
Current: $96.75
Upside: +65.37%
Dec 16, 2025
Maintains: Buy
Price Target: $25 → $35
Current: $21.70
Upside: +61.29%
Nov 7, 2025
Initiates: Buy
Price Target: $12
Current: $4.89
Upside: +145.40%
Nov 3, 2025
Upgrades: Buy
Price Target: $125
Current: $95.89
Upside: +30.36%
Aug 13, 2025
Reiterates: Buy
Price Target: $10
Current: $3.73
Upside: +168.10%
Aug 13, 2025
Reiterates: Buy
Price Target: $18
Current: $9.05
Upside: +98.90%
Aug 7, 2025
Maintains: Buy
Price Target: $16 → $15
Current: $11.21
Upside: +33.81%
Jul 8, 2025
Reiterates: Buy
Price Target: $17
Current: $36.95
Upside: -53.99%
Jun 24, 2025
Reiterates: Buy
Price Target: $45
Current: $25.25
Upside: +78.22%
May 23, 2025
Maintains: Buy
Price Target: $40 → $15
Current: $19.10
Upside: -21.47%
May 12, 2025
Reiterates: Buy
Price Target: $52
Current: $87.13
Upside: -40.32%
May 7, 2025
Maintains: Buy
Price Target: $30 → $10
Current: $14.51
Upside: -31.08%
May 6, 2025
Reiterates: Buy
Price Target: $32
Current: $24.56
Upside: +30.29%
Mar 24, 2025
Maintains: Buy
Price Target: $13 → $14
Current: $5.45
Upside: +156.88%
Mar 12, 2025
Reiterates: Neutral
Price Target: n/a
Current: $18.30
Upside: -
Feb 12, 2025
Reiterates: Buy
Price Target: $42
Current: $44.20
Upside: -4.98%
Jan 22, 2025
Reiterates: Buy
Price Target: n/a
Current: $2.29
Upside: -
Dec 6, 2024
Reiterates: Buy
Price Target: $20
Current: $5.22
Upside: +283.14%
Oct 7, 2024
Downgrades: Neutral
Price Target: n/a
Current: $31.85
Upside: -
Sep 30, 2024
Upgrades: Buy
Price Target: $112
Current: $6.55
Upside: +1,609.92%
May 15, 2024
Downgrades: Neutral
Price Target: n/a
Current: $4.60
Upside: -
Mar 14, 2024
Downgrades: Neutral
Price Target: n/a
Current: $5.50
Upside: -
Jan 5, 2024
Downgrades: Neutral
Price Target: n/a
Current: $2.70
Upside: -
Nov 8, 2023
Maintains: Buy
Price Target: $40 → $34
Current: $12.25
Upside: +177.55%
May 18, 2021
Initiates: Buy
Price Target: $26
Current: $2.66
Upside: +877.44%
Apr 28, 2021
Downgrades: Neutral
Price Target: n/a
Current: $3.55
Upside: -
Feb 15, 2019
Upgrades: Outperform
Price Target: $80
Current: $33.77
Upside: +136.90%
Jan 17, 2019
Initiates: Outperform
Price Target: n/a
Current: $7.30
Upside: -
Nov 7, 2017
Maintains: Market Perform
Price Target: $4 → $5.5
Current: $4.38
Upside: +25.57%